Broxyquinoline

Broxyquinoline (Dibromohydroxyquinoline) is an effective inhibitor of severe fever with thrombocytopenia syndrome virus (SFTSV) with an IC50 of 5.8 µM. Additionally, Broxyquinoline is an inhibitor of CpACBP1 with an IC50 of 64.9 μM. CpACBP1 is a fatty acyl-CoA binding protein of Cryptosporidium parvum, thus Broxyquinoline has the potential to inhibit parasite growth. Broxyquinoline shows promise for research in the field of infectious diseases[1][2].

Product Specifications

CAS Number

[521-74-4]

Product Name Alternative

Dibromohydroxyquinoline; 5,7-Dibromo-8-hydroxyquinoline

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Influenza Virus; Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Broxyquinoline.html

Purity

99.93

Solubility

DMSO : 31.25 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

OC1=C2N=CC=CC2=C(Br)C=C1Br

Molecular Formula

C9H5Br2NO

Molecular Weight

302.95

Precautions

H315, H319, H335

References & Citations

[1]Fritzler JM, et al. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP) . J Antimicrob Chemother. 2012 Mar;67 (3) :609-17.|[2]Shuofeng Yuan, et al. Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus. Viruses. 2019 Apr 25;11 (4) :385.|[3]Swetha R, et al. Organ directed toxicity of halquinol in a repeated dose 28 day oral toxicity study in female rats[J]. Indian Journal of Pharmacology, 2007, 39 (2) : 97-102.